PURPOSE: Multigene panel testing has increased the detection of germline mutations in patients with breast cancer. The implications of using radiation therapy (RT) to treat patients with pathogenic variant (PV) mutations are not well understood and have been studied mostly in women with only BRCA1 or BRCA2 PVs. We analyzed oncologic outcomes and toxicity after adjuvant RT in a contemporary, diverse cohort of patients with breast cancer who underwent genetic panel testing. METHODS AND MATERIALS: We retrospectively reviewed the records of 286 women with clinical stage I-III breast cancer diagnosed from 1995 to 2017 who underwent surgery, breast or chest wall RT with or without regional nodal irradiation, multigene panel testing, and evaluation at a large cancer center's genetic screening program. We evaluated rates of overall survival, locoregional recurrence, disease-specific death, and radiation-related toxicities in 3 groups: BRCA1/2 PV carriers, non-BRCA1/2 PV carriers, and patients without PV mutations. RESULTS: PVs were detected in 25.2% of the cohort (12.6% BRCA1/2 and 12.6% non-BRCA1/2). The most commonly detected non-BRCA1/2 mutated genes were ATM, CHEK2, PALB2, CDH1, TP53, and PTEN. The median follow-up time for the entire cohort was 4.4 years (95% confidence interval, 3.8-4.9 years). No differences were found in overall survival, locoregional recurrence, or disease-specific death between groups (P > .1 for all). Acute and late toxicities were comparable across groups. CONCLUSION: Oncologic and toxicity outcomes after RT in women with PV germline mutations detected by multigene pane testing are similar to those in patients without detectable mutations, supporting the use of adjuvant RT as a standard of care when indicated.
PURPOSE: Multigene panel testing has increased the detection of germline mutations in patients with breast cancer. The implications of using radiation therapy (RT) to treat patients with pathogenic variant (PV) mutations are not well understood and have been studied mostly in women with only BRCA1 or BRCA2 PVs. We analyzed oncologic outcomes and toxicity after adjuvant RT in a contemporary, diverse cohort of patients with breast cancer who underwent genetic panel testing. METHODS AND MATERIALS: We retrospectively reviewed the records of 286 women with clinical stage I-III breast cancer diagnosed from 1995 to 2017 who underwent surgery, breast or chest wall RT with or without regional nodal irradiation, multigene panel testing, and evaluation at a large cancer center's genetic screening program. We evaluated rates of overall survival, locoregional recurrence, disease-specific death, and radiation-related toxicities in 3 groups: BRCA1/2 PV carriers, non-BRCA1/2 PV carriers, and patients without PV mutations. RESULTS: PVs were detected in 25.2% of the cohort (12.6% BRCA1/2 and 12.6% non-BRCA1/2). The most commonly detected non-BRCA1/2 mutated genes were ATM, CHEK2, PALB2, CDH1, TP53, and PTEN. The median follow-up time for the entire cohort was 4.4 years (95% confidence interval, 3.8-4.9 years). No differences were found in overall survival, locoregional recurrence, or disease-specific death between groups (P > .1 for all). Acute and late toxicities were comparable across groups. CONCLUSION: Oncologic and toxicity outcomes after RT in women with PV germline mutations detected by multigene pane testing are similar to those in patients without detectable mutations, supporting the use of adjuvant RT as a standard of care when indicated.
Authors: Andrea Desmond; Allison W Kurian; Michele Gabree; Meredith A Mills; Michael J Anderson; Yuya Kobayashi; Nora Horick; Shan Yang; Kristen M Shannon; Nadine Tung; James M Ford; Stephen E Lincoln; Leif W Ellisen Journal: JAMA Oncol Date: 2015-10 Impact factor: 31.777
Authors: Timothy J Whelan; Ivo A Olivotto; Wendy R Parulekar; Ida Ackerman; Boon H Chua; Abdenour Nabid; Katherine A Vallis; Julia R White; Pierre Rousseau; Andre Fortin; Lori J Pierce; Lee Manchul; Susan Chafe; Maureen C Nolan; Peter Craighead; Julie Bowen; David R McCready; Kathleen I Pritchard; Karen Gelmon; Yvonne Murray; Judy-Anne W Chapman; Bingshu E Chen; Mark N Levine Journal: N Engl J Med Date: 2015-07-23 Impact factor: 91.245
Authors: Anne S Reiner; Mark E Robson; Lene Mellemkjær; Marc Tischkowitz; Esther M John; Charles F Lynch; Jennifer D Brooks; John D Boice; Julia A Knight; Sharon N Teraoka; Xiaolin Liang; Meghan Woods; Ronglai Shen; Roy E Shore; Daniel O Stram; Duncan C Thomas; Kathleen E Malone; Leslie Bernstein; Nadeem Riaz; Wendy Woodward; Simon Powell; David Goldgar; Patrick Concannon; Jonine L Bernstein Journal: J Natl Cancer Inst Date: 2020-12-14 Impact factor: 13.506
Authors: Carmen Bergom; Catharine M West; Daniel S Higginson; Mohamed E Abazeed; Banu Arun; Soren M Bentzen; Jonine L Bernstein; Jaden D Evans; Naamit K Gerber; Sarah L Kerns; Judy Keen; Jennifer K Litton; Anne S Reiner; Nadeem Riaz; Barry S Rosenstein; Gabriel O Sawakuchi; Simona F Shaitelman; Simon N Powell; Wendy A Woodward Journal: Int J Radiat Oncol Biol Phys Date: 2019-08-02 Impact factor: 7.038
Authors: Li Sun; Adam Brentnall; Shreeya Patel; Diana S M Buist; Erin J A Bowles; D Gareth R Evans; Diana Eccles; John Hopper; Shuai Li; Melissa Southey; Stephen Duffy; Jack Cuzick; Isabel Dos Santos Silva; Alec Miners; Zia Sadique; Li Yang; Rosa Legood; Ranjit Manchanda Journal: JAMA Oncol Date: 2019-10-03 Impact factor: 31.777